Press Releases

Intercytex announces two Board appointments

2nd August 2005, Cambridge , UK - Intercytex, the cell therapy company developing products for the advanced woundcare and aesthetic medicine markets, today announces two Board appointments. Alan Suggett (formerly Group Director of Technology, Smith & Nephew plc) and John Aston (Chief Financial Officer at Cambridge Antibody Technology Group plc) will be joining the Board at Intercytex with immediate effect.

Alan Suggett has 20 years of experience of operating at the technical/business interface in the medical devices field and in strategic and governance leadership, in particular related to R&D, clinical, regulatory, and environmental aspects. An early industrial champion of tissue engineering and cell therapy he has direct experience of the challenges involved in bringing such technologies into clinical practice. Until retiring from his full-time operational roles at the beginning of 2004, he was Group Director of Technology at Smith & Nephew plc and a long-standing member of the Company's Executive Committee. Previously he was Group R&D Director at Smith & Nephew and held senior positions with Scottish & Newcastle Breweries and Unilever Research.

John Aston is Chief Financial Officer of Cambridge Antibody Technology Group plc (CAT), a UK biopharmaceutical company listed on both the London Stock Exchange and NASDAQ. John joined CAT as CFO in 1996 where he subsequently took the company through a successful flotation on the London Stock Exchange in 1997, an international financing raising over £90 million in 2000 and a US listing on the NASDAQ National Market in 2001. Previously John was a Director in Corporate Finance at J. Henry Schroder & Co Ltd where he worked for 14 years. He qualified as a chartered accountant with Price Waterhouse and also worked with British Technology Group.

“I am delighted to welcome Alan and John to the Board – both of whom are highly experienced in their own fields,” said Ian Kent, Intercytex' Chairman. “I am confident that they will make an outstanding contribution to the next phase of Intercytex' development.”

Enquiries:

Intercytex
Nick Higgins, Chief Executive Officer: +44 (0)1223 421 962
Richard Moulson , Chief Financial Officer: +44 (0)161 904 4523

Financial Dynamics
David Yates/Davina Langdale: +44 (0) 207 831 3113

For further details about Intercytex, please visit www.intercytex.com

About Intercytex:

Intercytex is an emerging healthcare company developing cell therapy products for the woundcare and aesthetic medicine markets. It is using its proprietary expertise in cell therapy to develop products that harness the innate ability of human cells to regenerate and repair the body.

Intercytex has two products currently in clinical development, ICX-PRO and ICX-TRC. ICX-PRO is designed to actively stimulate repair in chronic wounds and will enter Phase III trials shortly. ICX-TRC is a hair regeneration product in Phase I trials. A third product, ICX-SKN, is in preclinical trials being developed as a true skin replacement to overcome the need for skin graft procedures. All Intercytex' products are derived from unmodified normal human cells.

Intercytex commenced operations in 2000 and has raised over £31 million in four private equity financing rounds. The Company has around 50 employees and is headquartered in Cambridge , UK with GMP clinical production facilities, research and development located in Manchester , UK and additional laboratories in Boston , MA.